4D Molecular Therapeutics (FDMT) Total Liabilities (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Total Liabilities of $61.1 million for Q1 2026, up 32.74% year-over-year from $46.0 million in Q1 2025, and little changed quarter-over-quarter from $61.0 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Total Liabilities (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Total Liabilities for 8 consecutive years, with $61.1 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities rose 32.74% year-over-year to $61.1 million; the TTM figure through Mar 2026 stood at $61.1 million (up 32.74% YoY), while the FY2025 annual figure was $61.0 million, up 22.64% from the prior year.
- Total Liabilities was little changed at $61.1 million in Q1 2026 per FDMT's latest filing, from $61.0 million in the prior quarter.
- Across five years, Total Liabilities topped out at $61.1 million in Q1 2026 and bottomed at $25.4 million in Q1 2023.
- Historically, Total Liabilities has averaged $39.6 million across 5 years, with a median of $31.8 million in 2024.
- Annual changes were most pronounced in 2022 — Total Liabilities surged 112.9% — and 2023, when it retreated 11.97%.
- 4D Molecular Therapeutics' Total Liabilities stood at $30.5 million in 2022, then advanced by 5.09% to $32.1 million in 2023, then surged by 55.26% to $49.8 million in 2024, then grew by 22.64% to $61.0 million in 2025, then rose by 0.04% to $61.1 million in 2026.
- Business Quant data shows FDMT's Total Liabilities at $61.1 million in Q1 2026, $61.0 million in Q4 2025, and $55.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.62 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 1.72 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 4.00 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 7.02 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 10.03 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 4.20 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 1.35 Bn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - | 84.96 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 84.96 Mn |
| Mar 31, 2026 | 61.07 Mn |
| Dec 31, 2025 | 61.05 Mn |
| Sep 30, 2025 | 55.00 Mn |
| Jun 30, 2025 | 52.75 Mn |
| Mar 31, 2025 | 46.01 Mn |
| Dec 31, 2024 | 49.78 Mn |
| Sep 30, 2024 | 51.08 Mn |
| Jun 30, 2024 | 31.78 Mn |
| Mar 31, 2024 | 29.32 Mn |
| Dec 31, 2023 | 32.06 Mn |
| Sep 30, 2023 | 31.68 Mn |
| Jun 30, 2023 | 27.36 Mn |
| Mar 31, 2023 | 25.42 Mn |
| Dec 31, 2022 | 30.51 Mn |
| Sep 30, 2022 | 28.72 Mn |
| Jun 30, 2022 | 30.42 Mn |
| Mar 31, 2022 | 28.87 Mn |
| Dec 31, 2021 | 34.38 Mn |
| Sep 30, 2021 | 16.48 Mn |